Company intelligence / Profile preview
Sequoia Pharmaceuticals
St. Louis, Missouri, United Statessequoiavaccines.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
SEQ-400 is a FimH vaccine in clinical investigation for recurrent UTIs, received FDA Fast Track designation in 2017; upcoming phase 2 efficacy trial will enroll patients as their own controls. Oncology program focused on small-molecule therapeutics for ovarian and other cancers; ongoing preclinical studies. Third program involves optimization of novel compounds for treating lung infections in cystic fibrosis patients.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sequoia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sequoia Pharmaceuticals.